New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
06:19 EDTVRX, AGNValeant bid for Allergan has 'significant hurdles,' says BMO Capital
BMO Capital believes fundamentally different views between managements will bring "significant hurdles" to Valeant's (VRX) desire to acquire the Botox maker. BMO thinks the significant cost cuts needed in order to make the acquisition work could damage the Allergan business. Also, the firm believes Allergan is likely to reject a Valeant bid that is 75% stock. BMO has an Outperform rating on shares of Allergan.
News For VRX;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 28, 2015
10:19 EDTVRXPershing Square lists Herbalife, Actavis as top Q1 losers
Subscribe for More Information
April 27, 2015
06:19 EDTVRXPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use